We are equally committed to people suffering from disorders of the central nervous system. People with these conditions need new, advanced therapies to treat them effectively. And we're working to discover, develop and deliver the treatments they need. Sunovion's targeted discovery and development program has already resulted in several treatments such as LUNESTA® (eszopiclone), a medicine that helps people sleep better.
Other development programs under way at Sunovion are focused on treating CNS conditions like anxiety, depression, and epilepsy, and schizophrenia. Latuda® (lurasidone HCl) tablets was approved by the U.S. Food and Drug Administration (FDA) on October 28, 2010 for the treatment of patients with schizophrenia. LATUDA is available by prescription in pharmacies across the United States and Puerto Rico.
A new name for a new company, Sunovion brings together two timeless forces: the sun's life-sustaining power and the human power of innovation. Together they represent the life-affirming energy that drives our vision and inspires our people, who strive to realize that vision every day. Our company symbol, the green prism, created by Dainippon Sumitomo Pharma, has long been a source of corporate pride among our colleagues in Japan. From its inception, this symbol has embodied the energy of the sun, the joy of good health, and the hope of the future. – less – More from ZoomInfo »